CRBU Stock Overview
A clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Caribou Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.96 |
| 52 Week High | US$8.33 |
| 52 Week Low | US$1.50 |
| Beta | 2.26 |
| 11 Month Change | -0.51% |
| 3 Month Change | -6.22% |
| 1 Year Change | -65.55% |
| 33 Year Change | -88.91% |
| 5 Year Change | n/a |
| Change since IPO | -87.99% |
Recent News & Updates
Recent updates
Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Shares Bounce 25% But Its Business Still Trails The Industry
Nov 05
Caribou Biosciences: CB-010, chRDNA Technology Continue To Show Promise In Gene Editing
Sep 30Here's Why We're Watching Caribou Biosciences' (NASDAQ:CRBU) Cash Burn Situation
Sep 06Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Share Price Boosted 39% But Its Business Prospects Need A Lift Too
Jul 26Caribou Biosciences: Promising Gene Editing Therapies With Strong Buy Potential
Jul 03Little Excitement Around Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Revenues As Shares Take 43% Pounding
Jun 05Caribou Biosciences: 2 Clinical Data Updates In 2024 Could Bring Value
Apr 18More Unpleasant Surprises Could Be In Store For Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Shares After Tumbling 25%
Apr 17Caribou Biosciences, Inc.'s (NASDAQ:CRBU) 25% Share Price Surge Not Quite Adding Up
Feb 15Caribou Biosciences: Under The Radar With Catalysts Approaching
Feb 01Caribou Biosciences (NASDAQ:CRBU) Is In A Good Position To Deliver On Growth Plans
Jan 10Caribou Biosciences, Inc.'s (NASDAQ:CRBU) 28% Price Boost Is Out Of Tune With Revenues
Nov 18Companies Like Caribou Biosciences (NASDAQ:CRBU) Are In A Position To Invest In Growth
Feb 24Caribou Biosciences: Strong Momentum Possible If Higher Dose Shows Durability
Oct 12Companies Like Caribou Biosciences (NASDAQ:CRBU) Are In A Position To Invest In Growth
Sep 16Caribou Biosciences: Potential To Change CAR-T Landscape
Aug 01Crispred CAR-T Cells In The Clinic
May 19Caribou Biosciences, Inc. (NASDAQ:CRBU) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
May 13Caribou Biosciences: Selling Close To Cash Balance
Apr 26We're Not Very Worried About Caribou Biosciences' (NASDAQ:CRBU) Cash Burn Rate
Oct 26Caribou Biosciences: Another Gene Editor Hurt By The Allogene Hold
Oct 12Shareholder Returns
| CRBU | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -10.9% | -6.5% | -1.0% |
| 1Y | -65.6% | 14.6% | 30.3% |
Return vs Industry: CRBU underperformed the US Biotechs industry which returned 14.1% over the past year.
Return vs Market: CRBU underperformed the US Market which returned 30.4% over the past year.
Price Volatility
| CRBU volatility | |
|---|---|
| CRBU Average Weekly Movement | 11.0% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CRBU's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CRBU's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 158 | Rachel Haurwitz | cariboubio.com |
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia.
Caribou Biosciences, Inc. Fundamentals Summary
| CRBU fundamental statistics | |
|---|---|
| Market cap | US$180.20m |
| Earnings (TTM) | -US$148.12m |
| Revenue (TTM) | US$11.48m |
15.5x
P/S Ratio-1.2x
P/E RatioIs CRBU overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CRBU income statement (TTM) | |
|---|---|
| Revenue | US$11.48m |
| Cost of Revenue | US$130.97m |
| Gross Profit | -US$119.49m |
| Other Expenses | US$28.63m |
| Earnings | -US$148.12m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.64 |
| Gross Margin | -1,041.33% |
| Net Profit Margin | -1,290.81% |
| Debt/Equity Ratio | 0% |
How did CRBU perform over the long term?
See historical performance and comparison